Drug-drug interactions: Proof of relevance (Part II): cause of tolerability problems or noncompliance.
Preskorn
Sheldon H
SH
Department of Psychiatry, University of Kansas School of Medicine-Wichita, Wichita, Kansas, USA.
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000494:pharmacology; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004347:Drug Interactions; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D018967:Risperidone / Q000009:adverse effects* / Q000494:pharmacology; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D016312:Treatment Refusal
D014150:Antipsychotic Agents; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D003577:Cytochrome P-450 Enzyme System; D018967:Risperidone; D017367:Selective Serotonin Reuptake Inhibitors